AANEM Education News Express

AANEM News Express

Science News: Polyneuropathy Relates to Impairment in Daily Activities, Worse Gait, and Fall-Related Injuries

    12/18/2017
Submitted by David B. Rosenfield, MD, News Science Editorial Board
Edited by Niranjan N. Singh, MD, News Science Editorial Board

A recent article from Neurology featured a population-based study in which activities of daily living were monitored in patients with polyneuropathy. 

Win an Award for Your Scientific Research!

    12/13/2017
Find out more about abstract awards you could win from the AANEM Foundation. Abstracts for 2018 will be accepted between January 1 and March 15, 2018.  

Science News: Tacrolimus Improves Symptoms of Children with Myasthenia Gravis Refractory to Prednisone

    12/13/2017
Submitted by Leigh Maria K. Ramos-Platt, MD, News Science Editorial Board
Edited by Niranjan N. Singh, MD, News Science Editorial Board


The latest article summary from the AANEM News Science Editorial Board covers an evaluation of the efficacy of Tacrolimus in Chinese pediatric autoimmune Myasthenia Gravis patients.

Science News: Chemotherapy-Induced Peripheral Neuropathy: A Current Review

    11/30/2017
Submitted by John C. Kincaid, MD, News Science Editorial Board
Edited by Niranjan N. Singh, MD, News Science Editorial Board

In the June 2017 edition of Annals of Neurology, Dr. Staff and his colleagues from Mayo Clinic in Rochester, Minnesota published a very detailed review article on chemotherapy-induced peripheral neuropathy (CIPN) which is a sensory predominant painful condition seen in 30-40 percent of patients receiving neurotoxic chemotherapy agents. In this review, they discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotype and pathomechanism of specific neurotoxic chemotherapeutic agents and treatment options.
 

Science News: Rise of Biomarkers – Part 4

    11/27/2017
Submitted by Nandita Keole, MD, News Science Editorial Board  
Edited by Francisco Gomez, MD, News Science Editorial Board
 
In “Rise of the Biomarkers – Part 4” (final segment of the biomarker series), researchers analyze skin biopsies of patients with diabetes mellitus (with and without diabetic neuropathy) and make some important discoveries. 

Science News: Rise of Biomarkers – Part 3

    11/21/2017
Submitted and edited by Francisco Gomez, MD, News Science Editorial Board
 
In “Rise of the Biomarkers – Part 3” (of a four-part series), biomarkers for Charcot-Marie-Tooth disease 1A are discussed. 

Science News: Rise of Biomarkers - Part 2

    11/7/2017
Over the past several months, an ever increasing number of articles on biomarkers have been published. The AANEM News Science Editorial Board is striving to keep our readers abreast of these recent discoveries.

In “Rise of the Biomarkers – Part 2” (of a four-part series), we cover how we have seen several advances in the diagnosis and evaluation of a number of peripheral nerve disorders, with focus on paranodal analyses and new uses for skin biopsy.

Additional article summaries on biomarkers will be forthcoming in subsequent AANEM publications. 

Science News: Rise of Biomarkers - Part 1

    10/24/2017
In “Rise of the Biomarkers – Part 1” (of a four-part series), we present new findings in the genetics of Amyotrophic Lateral Sclerosis (ALS). The article summary below outlines how genetic testing can provide new insights into the pathogenesis of Sporadic ALS, which may not be as sporadic as previously considered.

Additional article summaries on biomarkers will be forthcoming in subsequent AANEM publications.

Randomized Trial of Thymectomy in Myasthenia Gravis

    11/2/2016
This study in the New England Journal of Medicine demonstrates a clear clinical benefit of thymectomy in patients with non-thymomatous myasthenia gravis

Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs

    9/21/2016
This study in Neuron identified gain of toxicity as a main pathogenesis of GGGGCC-expanded C9ORF72 for ALS/FTD, and also proved the feasibility and effectiveness of antisense oligonucleotides-mediated therapy. 


First
Prev
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
Next
Last

Advertisement

TPP

Advertisement

ABEM

Advertisement

Find Your Dream Job